Boehringer In­gel­heim sharp­ens reti­nal strat­e­gy, scoop­ing up dry AMD drug from a Swiss team be­hind No­var­tis' Beovu

Boehringer In­gel­heim has inked a sec­ond deal for reti­nal dis­eases in a year — and this time it’s spe­cif­ic about which ail­ment to tar­get.

In a deal worth up to $490 mil­lion (CHF 474.5 mil­lion), the Ger­man phar­ma has locked in an an­ti­body frag­ment-based drug for ge­o­graph­ic at­ro­phy from Zurich, Switzer­land-based CDR-Life. Boehringer al­so gets a li­cense to de­vel­op and com­mer­cial­ize oth­er com­pounds against the spe­cif­ic tar­get.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.